Scientists attempt to cure blindness with gene therapy – The Times
The Times |
Scientists attempt to cure blindness with gene therapy
The Times Irish scientists are attempting to cure one of the most common forms of blindness through gene therapy. Retinitis pigmentosa, which affects about 1,500 people in Ireland, is caused by a faulty gene which causes the light-sensitive retina in the eye to … Irish scientists using ‘Trojan horse’ gene to fight inherited blindnessIndependent.ie |
WHBL Sheboygan |
Multiple gene therapy trials report high remission rates for certain lymphoma patients
Xinhua WASHINGTON, Dec. 10 (Xinhua) — In three clinical trials conducted in multiple sites, a novel gene therapy that genetically engineers a patient’s immune system to attack cancer cells demonstrated long-lasting remissions in certain lymphoma patients … Phase 2 CAR-T study reports significant remission rates at 15-month follow upMedical Xpress |
Endpoints News |
CAR T, immunotherapy bring new hope for multiple myeloma patients
EurekAlert (press release) PHILADELPHIA – Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other therapies … ‘Unheard of’ responses to bluebird CAR-T therapy seen in myeloma studyReuters Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 …Business Wire (press release) |
|
ASH17: Benefit of Gilead’s CAR–T remains durable over longer term
BioPharma Dive Updated results from a pivotal study of Gilead Sciences Inc.’s CAR–T therapy Yescarta offers new proof of the treatment’s benefit over the longer term, suggesting those patients who go into remission are likely to remain so more than one year after … |
Reuters |
Novartis CAR–T therapy leads to durable response in lymphoma study
Reuters Kymriah belongs to an exciting new class of therapy called CAR-T. It works by harvesting a patient’s own disease-fighting T–cells, genetically engineering them to target specific proteins on cancer cells, and replacing them to circulate possibly for … Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete …GlobeNewswire (press release) #ASH17: How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR–T showdown with Gilead?Endpoints News |